Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Evolus, Inc., the most common co-covered peer. David Moatazedi appears in 1 tracked Biotech story from March 5, 2026. The tracked stories average 4 original sources each.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Evolus, Inc., the most common co-covered peer. David Moatazedi appears in 1 tracked Biotech story from March 5, 2026. The tracked stories average 4 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering David Moatazedi. Shared-story counts are live from our verified record — not editorial picks.
Anticipated FDA Approval
Expected regulatory clearance for the first Evolysse filler products.
Commercial Launch
Planned U.S. launch of the Evolysse filler portfolio to aesthetic injectors.
Q4 Earnings
Company reports record revenue and market share for Jeuveau.
Filler Partnership
Evolus expands partnership with Symatese for the Evolysse dermal filler line.
Evolus, Inc. reported strong Q4 2025 results, driven by the continued market share expansion of its flagship neurotoxin, Jeuveau, and progress in its international rollout. The company remains on track to transform into a multi-product aesthetics platform with the anticipated 2026 launch of its Evolysse dermal filler line.
David Moatazedi is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
